Journal of Addiction Research & Therapy
Open Access

BLUM R (2014) SPORTS: FYI. SAT 1:11.

Blum K, Oscar-Berman M, Braverman ER, Febo M, Li M, et al. (2015) Enhancing brain pregnenolone may protect cannabis intoxication but should not be considered as an anti-addiction therapeutic: hypothesizing dopaminergic blockade and promoting anti-reward. Journal of reward deficiency syndrome 1: 20.

Blum K, Oscar-Berman M, Blum SH, Madigan MA, Waite RL, et al. (2014) Can Genetic Testing Coupled with Enhanced Dopaminergic Activation Reduce Recidivism Rates in the Workers Compensation Legacy Cases?. Journal of alcoholism and drug dependence 2.

Blum K, Febo M, Badgaiyan RD (2016) Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial. Austin addiction sciences 1.

Blum K, Oscar-Berman M, Waite RL, Braverman ER, et al. (2014) A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain. Journal of genetic syndromes & gene therapy 5: 213.

Miller D, Miller M, Blum K, Badgaiyan RD, Febo M (2015) Addiction Treatment in America: After Money or Aftercare?. Journal of reward deficiency syndrome 1.

Blum K, Han D, Giordano J, Lohmann R, Braverman ER, et al. (2013) Neurogenetics and Nutrigenomics of Reward Deficiency Syndrome (RDS): Stratification of Addiction Risk and Mesolimbic Nutrigenomic Manipulation of Hypodopaminergic Function. InOmics for Personalized Medicine: 365-398.

Blum K, Febo M, D Badgaiyan R, Demetrovics Z, Simpatico T, et al. (2017) Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape. Current neuropharmacology 15: 184-194.

Blum K, Berman MO, Braverman ER, Gold MS (2014) Raising endogenous brain levels of kynurenic acid may produce anti-reward and enhance suicide ideation. J Alcohol Drug Depend 2: 151.

Blum K, Badgaiyan RD, Angres DH, Gold MS (2015) Should We Embrace Vaccines for Treating Substance-Related Disorder, A Subset of Reward Deficiency Syndrome (RDS)?. Journal of reward deficiency syndrome 1.

McLaughlin T, Febo M, Badgaiyan RD, Barh D, Dushaj K, et al. (2016) KB220Z™ a pro-dopamine regulator associated with the protracted, alleviation of terrifying lucid dreams. Can we infer neuroplasticity-induced changes in the reward circuit?. Journal of reward deficiency syndrome and addiction science 2: 3.

Waite RL, Oscar-Berman M, RBraverman E, Barh D, Blum K (2014) Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro-Adaptive Therapy 12™[NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications. Journal of addiction research & therapy 5: 1.

Blum K, Badgaiyan RD, Demotrovics Z, Fratantonio J, Agan G, et al. (2015) Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?. Clinical medical reviews and case reports 2.

Blum K, Febo M, Fahlke C, Archer T, Berggren U, et al. (2015) Hypothesizing balancing endorphinergic and glutaminergic systems to treat and prevent relapse to reward deficiency behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a novel therapeutic modality. Clinical medical reviews and case reports 2.

Blum K, Febo M, Smith DE, Roy III AK, Demetrovics Z, et al. (2015) Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation. Journal of child and adolescent psychopharmacology 25: 286-292.

Blum K, Simpatico T, Badgaiyan RD, Demetrovics Z, Fratantonio J, et al. (2015) Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms. Journal of reward deficiency syndrome 1: 75.

Steinberg B, Blum K, McLaughlin T, Lubar J, Febo M, et al. (2016) Low-Resolution Electromagnetic Tomography (LORETA) of changed brain function provoked by pro-dopamine regulator (KB220z) in one adult ADHD case. Open journal of clinical & medical case reports 2.

Blum K, Schoenthaler SJ, Oscar-Berman M, Giordano J, Madigan MA, et al. (2014) Drug abuse relapse rates linked to level of education: Can we repair hypodopaminergic-induced cognitive decline with nutrient therapy?. The Physician and sportsmedicine 42: 130-145.

Huhn AS, Meyer RE, Harris JD, Ayaz H, Deneke E, et al. (2016) Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. Brain research bulletin 123: 102-109.

Alguacil LF, González-Martín C (2015) Target identification and validation in brain reward dysfunction. Drug discovery today 20: 347-352.